Please assess the completion status of the following clinical trial:

Trial Title: Dräger COVID-19 Antigen Test Clinical Performance Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must require SARS-CoV-2 testing for the following reasons:~  * COVID-19 symptoms (Fever, cough and/or sore throat, fatigue/ general feeling of weakness, loss of sense of smell and/or taste, shortness of breath, muscle stiffness/ body aches, head cold/ running nose, etc.) on the day of testing, or~ * Known or suspected exposure to SARS-CoV-2 (contact persons etc.), or~ * Member of a group of high risk of exposure such as healthcare workers etc., or~ * Require screening for any other reason, e.g. doctor's orders, hygiene directive etc.~* Participant must be of legal age and must be able to understand the procedure and letter of consent.~Exclusion Criteria:~* Patients younger than 18 years old are excluded from the study.~* Pregnant or breastfeeding patients are excluded from the study.~* Patients unable to provide written informed consent are excluded.~* Patients with bleeding disorder are excluded from the study as a precaution.~* Hospitalized patients/inpatients are excluded.~* Application of nasal spray within 15 min prior to testing.~* Participants with symptoms on the day of testing are excluded, if any of their symptoms started more than 14 days prior to testing.~* Asymptomatic participants are excluded, if they experienced any symptoms in the 14 days prior to testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptomatic (Type: OTHER): Collection of specimens from symptomatic COVID-19 positive participants
- Asymptomatic (Type: OTHER): Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2

Based on this trial design, predict the completion outcome and termination type (if applicable).